Abzena announces appointment of Jeffrey Mocny as Scientific Lead

13th July 2022

Abzena, the leading Partner Research Organization (PRO) providing integrated discovery, development and manufacturing of biologics and antibody drug conjugates (ADCs) has announced the appointment of Jeffrey Mocny, Ph.D. as scientific lead.

Reporting to Abzena’s Head of Scientific Leaders, Dr. Petra Dieterich, Dr Mocny will use his extensive experience with biopharmaceutical regulations to support Abzena’s successful drug development and manufacturing operations, ultimately assisting in getting more successful treatments to patients.

Dr Petra Dieterich, Head of Scientific Leaders at Abzena, said: “Jeff is an excellent addition for both the Abzena team and our partners.

“He will apply his expertise to support our partners in the submission of their regulatory filings in both the US and EU, alongside recommending regulatory strategies to speed up product development. This appointment supports our expanded investments in all stages of drug development and manufacturing, and I know his knowledge and experience will be vital in the implementation of Abzena’s integrated capabilities. I am delighted to welcome Jeff to the team and for our partners to benefit from his wealth of experience in the whole regulatory process.”

Dr. Mocny most recently served as senior vice president, regulatory affairs at ProEd Regulatory, a communications agency with expertise in medical communications and strategy.

He joins Abzena with more than three decades’ experience of working in drug development with a focus on regulatory strategy. A PhD microbiologist by training, Jeff has wide-ranging experience in working in a CRO environment across different stages of the drug development and manufacturing lifecycle including analytical method development, CMC regulatory affairs and IP to Phase I.

Jeff said: “Abzena is a company with great ambition and has already shown a comprehensive track record in transitioning complex molecules through lead selection into clinical development in multiple therapeutic areas. I’m looking forward to working with the team to optimize client programs and help steer Abzena through its next stages of growth.”